Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 133.00 | |
2 mg | In stock | $ 198.00 | |
5 mg | In stock | $ 298.00 | |
10 mg | In stock | $ 453.00 | |
25 mg | In stock | $ 747.00 | |
50 mg | In stock | $ 1,050.00 | |
100 mg | In stock | $ 1,420.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 373.00 |
Description | DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells. |
In vivo | In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. |
Molecular Weight | 489.94 |
Formula | C15H8Br3NO3 |
CAS No. | 1685280-21-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (51.03 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DMH-25 1685280-21-0 PI3K/Akt/mTOR signaling mTOR DMH 25 DMH25 inhibitor inhibit